Tammy Romo Sells 645 Shares of Tenet Healthcare (NYSE:THC) Stock

Tenet Healthcare Corporation (NYSE:THC) Director Tammy Romo sold 645 shares of the stock in a transaction on Wednesday, November 5th. The stock was sold at an average price of $205.20, for a total value of $132,354.00. Following the sale, the director directly owned 34,866 shares in the company, valued at approximately $7,154,503.20. This trade represents a 1.82% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Tammy Romo also recently made the following trade(s):

• On Tuesday, November 4th, Tammy Romo sold 11,756 shares of Tenet Healthcare stock. The stock was sold at an average price of $204.07, for a total transaction of $2,399,046.92.
• On Monday, November 3rd, Tammy Romo sold 15,099 shares of Tenet Healthcare stock. The shares were sold at an average price of $200.81, for a total transaction of $3,032,030.19.

Tenet Healthcare Stock Performance

NYSE THC opened at $204.99 on Friday. The firm’s 50 day simple moving average is $198.15 and its 200 day simple moving average is $176.14. The firm has a market capitalization of $18.02 billion, a price-to-earnings ratio of 14.05, a P/E/G ratio of 0.89 and a beta of 1.53. The company has a current ratio of 1.71, a quick ratio of 1.63 and a debt-to-equity ratio of 2.27. Tenet Healthcare Corporation has a 1 year low of $109.82 and a 1 year high of $217.43.

Tenet Healthcare (NYSE:THC) last released its earnings results on Tuesday, October 28th. The company reported $3.70 earnings per share for the quarter, topping the consensus estimate of $3.33 by $0.37. Tenet Healthcare had a return on equity of 25.11% and a net margin of 6.49%.The firm had revenue of $5.29 billion during the quarter, compared to analysts’ expectations of $5.26 billion. During the same period in the prior year, the company earned $2.93 earnings per share. The company’s quarterly revenue was up 3.2% on a year-over-year basis. Tenet Healthcare has set its FY 2025 guidance at 15.930-16.26 EPS. As a group, research analysts expect that Tenet Healthcare Corporation will post 12.24 earnings per share for the current fiscal year.

Institutional Trading of Tenet Healthcare

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD grew its position in shares of Tenet Healthcare by 6.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 7,596,544 shares of the company’s stock valued at $1,021,736,000 after buying an additional 463,552 shares during the last quarter. Boston Partners lifted its stake in shares of Tenet Healthcare by 95.0% in the second quarter. Boston Partners now owns 2,267,142 shares of the company’s stock worth $398,949,000 after acquiring an additional 1,104,500 shares during the period. Ameriprise Financial Inc. boosted its holdings in Tenet Healthcare by 8.0% in the second quarter. Ameriprise Financial Inc. now owns 2,119,423 shares of the company’s stock valued at $373,020,000 after acquiring an additional 157,109 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in Tenet Healthcare by 12.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,675,199 shares of the company’s stock worth $225,297,000 after purchasing an additional 181,667 shares during the last quarter. Finally, Nuveen LLC acquired a new position in shares of Tenet Healthcare in the 1st quarter worth approximately $218,549,000. 95.44% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have commented on THC. Wells Fargo & Company boosted their target price on Tenet Healthcare from $200.00 to $238.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 7th. Truist Financial reiterated a “buy” rating and set a $240.00 price objective (up from $225.00) on shares of Tenet Healthcare in a research report on Monday, November 3rd. Cantor Fitzgerald raised their target price on shares of Tenet Healthcare from $190.00 to $245.00 and gave the company an “overweight” rating in a research report on Wednesday, October 29th. Zacks Research downgraded shares of Tenet Healthcare from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th. Finally, Wall Street Zen raised Tenet Healthcare from a “hold” rating to a “strong-buy” rating in a report on Saturday, July 26th. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Tenet Healthcare has an average rating of “Moderate Buy” and a consensus price target of $226.25.

About Tenet Healthcare

Tenet Healthcare Corporation operates as a diversified healthcare services company in the United States. The company operates through two segments: Hospital Operations and Services, and Ambulatory Care. Its general hospitals offer acute care services, operating and recovery rooms, radiology and respiratory therapy services, clinical laboratories, and pharmacies.